 |
| ▲ This undated image, provided by South Korean biopharmaceutical company Celltrion Inc., shows its DiaTrust COVID-19 Ag Home Test. (PHOTO NOT FOR SALE) (Yonhap) |
Celltrion USA-sales
Celltrion USA sales skyrocket 36 times on-year in 2021
By Kim Han-joo
SEOUL, March 21 (Yonhap) -- The U.S. subsidiary of South Korean biopharmaceutical company Celltrion Inc. logged record high sales in the U.S. market last year on the back of robust sales of its self-diagnostic kit for COVID-19, officials said Monday.
The annual revenue of Celltrion USA, Inc., the wholly owned subsidiary of Celltrion, reached 84.6 billion won (US$69.6 million) in 2021, sharply up from 2.36 billion won a year earlier.
The Celltrion DiaTrust COVID-19 Ag Home Test, co-developed by Humasis Co., received the U.S. Food and Drug Administration's Emergency Use Authorization approval.
The product is also supplied through Amazon after Celltrion directly signed a contract with the world's largest online retailer.
Celltrion said Amazon directly buys the self-test kits from Celltrion USA without going through wholesalers.
(END)
(C) Yonhap News Agency. All Rights Reserved
